Sphingolipid signaling and hematopoietic malignancies: To the rheostat and beyond

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 9, 2011, Pages 782-793

  Loh, Kenneth C ^a   Baldwin, Dianna ^a   Saba, Julie D ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

Cancer; Ceramide; Chemotherapy; Leukemia; Lymphoma; Multiple myeloma; Sphingolipid; Sphingosine 1 phosphate

Indexed keywords

3 (4 CHLOROPHENYL)ADAMANTANE 1 CARBOXYLIC ACID (PYRIDIN 4 YLMETHYL)AMIDE; ABC 294640; ANTHRACYCLINE DERIVATIVE; BML 258; CERAMIDE; DOXORUBICIN; ETOPOSIDE; FINGOLIMOD; IMATINIB; SAFINGOL; SPHINGOLIPID; SPHINGOMAB; SPHINGOSINE 1 PHOSPHATE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANGIOGENESIS; APOPTOSIS; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER CELL CULTURE; CANCER RESISTANCE; CARDIOTOXICITY; CELL CYCLE PROGRESSION; CELL FATE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNITY; INFLAMMATION; LARGE CELL LYMPHOMA; LEUKEMIA; LIVER TOXICITY; LYMPHOMA; MANTLE CELL LYMPHOMA; MODEL; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; SENESCENCE; SIGNAL TRANSDUCTION; SOLID TUMOR; TRANSCRIPTION REGULATION;

EID: 80054086856     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011797655159     Document Type: Article

References (146)

1. Ghosh, T.; Bian, J.; Gill, D., Intracellular calcium release by sphingosine derivatives generated in cells. Science, 1990, 248, 1653-1656.
2. Sadahira, Y.; Ruan, F.; Hakomori, S.; Igarashi, Y., Sphingosine 1- phosphate, a specific endogenous signaling molecule controlling cell motility and tumor cell invasiveness. Proc. Natl. Acad. Sci. USA, 1992, 89, 9686-9690.
3. Zhang, H.; Desai, N.; Olivera, A.; Seki, T.; Brooker, G.; Spiegel, S., Sphingosine-1-Phosphate, a novel lipid, involved in cellular proliferation. J. Cell Biol., 1991, 114 (1), 155-167.
4. Olivera, A.; Spiegel, S., Sphingosine 1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens. Nature, 1993, 365, 557-559.
5. Okazaki, T.; Bell, R.; Hannun, Y., Sphingomyelin turnover induced by vitamin D3 in HL-60 cells. J. Biol. Chem., 1989, 264 (32), 19076-19080.
6. Obeid, L.; Linardic, C.; Karolak, L.; Hannun, Y., Programmed cell death induced by ceramide. Science, 1993, 259, 1769-1771.
7. Cuvillier, O.; Pirianov, G.; Kleuser, B.; Vanek, P. G.; Coso, O. A.; Gutkind, S.; Spiegel, S., Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature, 1996, 381 (6585), 800-803.
8. Cuvillier, O.; Rosenthal, D. S.; Smulson, M. E.; Spiegel, S., Sphingosine 1-phosphate inhibits activation of caspases that cleave poly(ADP-ribose) polymerase and lamins during Fas- and ceramide- mediated apoptosis in Jurkat T lymphocytes. J. Biol. Chem., 1998, 273 (5), 2910-2916.
9. Fyrst, H.; Saba, J., An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat. Chem. Biol., 2010, 6 (7), 489-497.
10. Kobayashi, N.; Yamaguchi, A.; Nishi, T., Characterization of the ATP-dependent sphingosine 1-phosphate transporter in rat erythrocytes. J. Biol. Chem., 2009, 284 (32), 21192-21200.
11. Mitra, P.; Oskeritzian, C. A.; Payne, S. G.; Beaven, M. A.; Milstien, S.; Spiegel, S., Role of ABCC1 in export of sphingosine-1- phosphate from mast cells. Proc. Natl. Acad. Sci. USA, 2006, 103 (44), 16394-16399.
12. Kawahara, A.; Nishi, T.; Hisano, Y.; Fukui, H.; Yamaguchi, A.; Mochizuki, N., The sphingolipid transporter spns2 functions in migration of zebrafish myocardial precursors. Science, 2009, 323, 524-527.
13. Kim, R. H.; Takabe, K.; Milstien, S.; Spiegel, S., Export and functions of sphingosine-1-phosphate. Biochim. Biophys. Acta, 2009.
14. Xia, P.; Gamble, J. R.; Wang, L.; Pitson, S. M.; Moretti, P. A.; Wattenberg, B. W.; D'Andrea, R. J.; Vadas, M. A., An oncogenic role of sphingosine kinase. Curr. Biol., 2000, 10 (23), 1527-1530.
15. French, K.; Schrecengost, R.; Lee, B.; Zhuang, Y.; Smith, S.; Eberly, J.; Yun, J.; Smith, C., Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res., 2003, 63, 5962-5969.
16. Ponnusamy, S.; Meyers-Needham, M.; Senkal, C. E.; Saddoughi, S. A.; Sentelle, D.; Selvam, S. P.; Salas, A.; Ogretmen, B., Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance. Future Oncol., 2010, 6 (10), 1603-1624.
17. Lavieu, G.; Scarlatti, F.; Sala, G.; Carpentier, S.; Levade, T.; Ghidoni, R.; Botti, J.; Codogno, P., Regulation of autophagy by sphingosine kinase 1 and its role in cell survival during nutrient starvation. J. Biol. Chem., 2006, 281, 8518-8527.
18. Senkal, C. E.; Ponnusamy, S.; Bielawski, J.; Hannun, Y. A.; Ogretmen, B., Antiapoptotic roles of ceramide-synthase-6-generated C16-ceramide via selective regulation of the ATF6/CHOP arm of ER-stress-response pathways. FASEB J., 2010, 24 (1), 296-308.
19. Hagen, N.; Van Veldhoven, P. P.; Proia, R. L.; Park, H.; Merrill, A. H., Jr.; Van Echten-Deckert, G., Subcellular origin of sphingosine- 1-phosphate is essental for its toxic effect in lyase deficient neurons. J. Biol. Chem. 2009.
20. Spiegel, S.; Kolesnick, R., Sphingosine-1-phosphate as a therapeutic agent. Leukemia, 2002, 16, 1596-602.
21. Oskouian, B.; Saba, J., Cancer treatment strategies targeting sphingolipid metabolism. In Sphingolipids as Signaling and Regulatory Molecules, Chalfant, C. E.; Del Poeta, M., Eds. Landes Bioscience: Austin, TX, 2009; p (in press).
22. Shida, D.; Takabe, K.; Kapitonov, D.; Milstien, S.; Spiegel, S., Targeting SphK1 as a new strategy against cancer. Curr Drug Targets, 2008, 9 (8), 662-673.
23. Pyne, N. J.; Pyne, S., Sphingosine 1-phosphate and cancer. Nat. Rev. Cancer, 2010, 10 (7), 489-503.
24. Patwardhan, G. A.; Liu, Y.-Y., Sphingolipids and expression regulation of genes in cancer. Prog. Lipid Res., 2011, 50 (1), 104-114.
25. Gault, C. R.; Obeid, L. M.; Hannun, Y. A., An overview of sphingolipid metabolism: from synthesis to breakdown. Adv. Exp. Med. Biol., 2010, 688, 1-23.
26. Spiegel, S.; Milstien, S., Functions of the multifaceted family of sphingosine kinases and some close relatives. J. Biol. Chem. 2006.
27. Jarman, K. E.; Moretti, P. A.; Zebol, J. R.; Pitson, S. M., Translocation of sphingosine kinase 1 to the plasma membrane is mediated by calcium- and integrin-binding protein 1. J. Biol. Chem., 2010, 285 (1), 483-492.
28. Hait, N. C.; Allegood, J.; Maceyka, M.; Strub, G. M.; Harikumar, K. B.; Singh, S. K.; Luo, C.; Marmorstein, R.; Kordula, T.; Milstien, S.; Spiegel, S., Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science, 2009, 325 (5945), 1254-1257.
29. Liu, H.; Toman, R. E.; Goparaju, S.; Maceyka, M.; Nava, V. E.; Sankala, H.; Payne, S. G.; Bektas, M.; Ishii, I.; Chun, J.; Milstien, S.; Spiegel, S., Sphingosine kinase type 2 is a putative BH3-Only protein that induces apoptosis. J. Biol. Chem., 2003, 278, 40330-40336.
30. Mandala, S. M., Sphingosine-1-phosphate phosphatases. Prostaglandins Other Lipid Mediat., 2001, 64 (1-4), 143-156.
31. Serra, M.; Saba, J. D., Sphingosine 1-phosphate lyase, a key regulator of sphingosine 1-phosphate signaling and function. Adv. Enzyme Regul., 2010, 50 (1), 349-362.
32. Colie, S.; Van Veldhoven, P. P.; Kedjouar, B.; Bedia, C.; Albinet, V.; Sorli, S. C.; Garcia, V.; Djavaheri-Mergny, M.; Bauvy, C.; Codogno, P.; Levade, T.; Andrieu-Abadie, N., Disruption of sphingosine 1-phosphate lyase confers resistance to chemotherapy and promotes oncogenesis through Bcl-2/Bcl-xL upregulation. Cancer Res., 2009, 69 (24), 9346-9353.
33. Min, J.; Stegner, A.; Alexander, H.; Alexander, S., Overexpression of sphingosine-1-phosphate lyase or inhibition of sphingosine kinase in Dictyostelium discoideum results in a selective increase in sensitivity to platinum-based chemotherapy drugs. Eukaryotic Cell, 2004, 3.
34. Oskouian, B.; Sooriyakumaran, P.; Borowsky, A.; Crans, A.; Dillard- Telm, L.; Tam, Y.; Bandhuvula, P.; Saba, J., Sphingosine-1- phosphate lyase potentiates apoptosis via p53- and p38-dependent pathways and is downregulated in colon cancer. Proc. Natl. Acad. Sci. USA, 2006, 103, 17384-17389.
35. Johnson, K. R.; Johnson, K. Y.; Becker, K. P.; Bielawski, J.; Mao, C.; Obeid, L. M., Role of human sphingosine-1-phosphate phosphatase 1 in the regulation of intra- and extracellular sphingosine- 1-phosphate levels and cell viability. J. Biol. Chem., 2003, 278 (36), 34541-34547.
36. Le Stunff, H.; Galve-Roperh, I.; Peterson, C.; Milstien, S.; Spiegel, S., Sphingosine-1-phosphate phosphohydrolase in regulation of sphingolipid metabolism and apoptosis. J. Cell Biol., 2002, 158 (6), 1039-1049.
37. Gomez-Munoz, A.; Duffy, P.; Martin, A.; O'Brien, L.; Byun, H.; Bittman, R.; Brindley, D., Short-chain ceramide-1-phosphates are novel stimulators of DNA synthesis and cell division: antagonism by cell-permeable ceramides. Mol. Pharmacol., 1995, 47 (5), 833-839.
38. Lamour, N. F.; Chalfant, C. E., Ceramide kinase and the ceramide- 1-phosphate/cPLA2alpha interaction as a therapeutic target. Curr. Drug Targets, 2008, 9 (8), 674-682.
39. Skoura, A.; Hla, T., Lysophospholipid receptors in vertebrate development, physiology, and pathology. J. Lipid Res., 2009, 50 Suppl, S293-S298.
40. Rosen, H.; Goetzl, E. J., Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat. Rev. Immunol., 2005, 5 (7), 560-570.
41. Hobson, J. P.; Rosenfeldt, H. M.; Barak, L. S.; Olivera, A.; Poulton, S.; Caron, M. G.; Milstien, S.; Spiegel, S., Role of the sphingosine- 1-phosphate receptor EDG-1 in PDGF-induced cell motility. Science, 2001, 291 (5509), 1800-1803.
42. Westwick, J. K.; Bielawska, A. E.; Dbaibo, G.; Hannun, Y. A.; Brenner, D. A., Ceramide activates the stress-activated protein kinases. J. Biol. Chem., 1995, 270 (39), 22689-22692.
43. Kim, H. J.; Mun, J. Y.; Chun, Y. J.; Choi, K. H.; Kim, M. Y., Baxdependent apoptosis induced by ceramide in HL-60 cells. FEBS Lett., 2001, 505 (2), 264-268.
44. Laurent, G.; Jaffrezou, J. P., Signaling pathways activated by daunorubicin. Blood, 2001, 98 (4), 913-924.
45. Haimovitz-Friedman, A.; Kan, C.; Ehleiter, D.; Persaud, R.; McLoughlin, M.; Fuks, Z.; Kolesnick, R., Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J. Exp. Med., 1994, 180, 525-535.
46. Dbaibo, G.; Obeid, L.; Hannun, Y., Tumor necrosis factor- (TNF-) signal transduction through ceramide. J. Biol. Chem., 1993, 268 (24), 17762-17766.
47. Schütze, S.; Machleidt, T.; Krönke, M., The role of diacylglycerol and ceramide in tumor necrosis factor and interleukin-1 signal transduction. J. Leukoc. Biol., 1994, 56, 533-541.
48. Takeda, Y.; Tashima, M.; Takahashi, A.; Uchiyama, T.; Okazaki, T., Ceramide generation in nitric oxide-induced apoptosis. Activation of magnesium-dependent neutral sphingomyelinase via caspase-3. J. Biol. Chem., 1999, 274 (15), 10654-10660.
49. Cremesti, A.; Paris, F.; Grassme, H.; Holler, N.; Tschopp, J.; Fuks, Z.; Gulbins, E.; Kolesnick, R., Ceramide enables fas to cap and kill. J. Biol. Chem., 2001, 276 (26), 23954-23961.
50. Hannun, Y. A., Functions of ceramide in coordinating cellular responses to stress. Science,1996, 274 (5294), 1855-1859.
51. Perez, G. I.; Knudson, C. M.; Leykin, L.; Korsmeyer, S. J.; Tilly, J. L., Apoptosis-associated signaling pathways are required for chemotherapy- mediated female germ cell destruction [see comments]. Nat. Med., 1997, 3 (11), 1228-1232.
52. Bose, R.; Verheij, M.; Haimovitz-Friedman, A.; Scotto, K.; Fuks, Z.; Kolesnick, R., Ceramide synthase mediates daunorubicininduced apoptosis: an alternative mechanism for generating death signals. Cell, 1995, 82 (3), 405-414.
53. Franzen, R.; Pfeilschifter, J.; Huwiler, A., Nitric oxide induces neutral ceramidase degradation by the ubiquitin/proteasome complex in renal mesangial cell cultures. FEBS Lett., 2002, 532 (3), 441-444.
54. Choi, M. S.; Anderson, M. A.; Zhang, Z.; Zimonjic, D. B.; Popescu, N.; Mukherjee, A. B., Neutral ceramidase gene: role in regulating ceramide-induced apoptosis. Gene, 2003, 315, 113-122.
55. Lafont, E.; Milhas, D.; Carpentier, S.; Garcia, V.; Jin, Z. X.; Umehara, H.; Okazaki, T.; Schulze-Osthoff, K.; Levade, T.; Benoist, H.; Segui, B., Caspase-mediated inhibition of sphingomyelin synthesis is involved in FasL-triggered cell death. Cell Death Differ., 2010, 17 (4), 642-654.
56. Smyth, M. J.; Perry, D. K.; Zhang, J.; Poirier, G. G.; Hannun, Y. A.; Obeid, L. M., prICE: a downstream target for ceramide-induced apoptosis and for the inhibitory action of Bcl-2. Biochem. J., 1996, 316 (Pt 1), 25-28.
57. Wolff, R.; Dobrowsky, R.; Bielawska, A.; Obeid, L.; Hannun, Y., Role of ceramide-activated protein phosphatase in ceramidemediated signal transduction. J. Biol. Chem., 1994, 269 (30), 19605-19609.
58. Dobrowsky, R.; Kamibayashi, C.; Mumby, M.; Hannun, Y., Ceramide activates a heterotrimeric protein phosphatase 2A. J. Biol. Chem., 1993, 268 (21), 15523-15530.
59. Mondal, S.; Mandal, C.; Sangwan, R.; Chandra, S., Withanolide D induces apoptosis in leukemia by targeting the activation of neutral sphingomyelinase-ceramide cascade mediated by synergistic activation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase. Mol. Cancer, 2010, 9, 239.
60. Jarvis, W. D.; Fornari, F. A., Jr.; Auer, K. L.; Freemerman, A. J.; Szabo, E.; Birrer, M. J.; Johnson, C. R.; Barbour, S. E.; Dent, P.; Grant, S., Coordinate regulation of stress- and mitogen-activated protein kinases in the apoptotic actions of ceramide and sphingosine. Mol. Pharmacol., 1997, 52 (6), 935-947.
61. Liu, X.; Ryland, L.; Yang, J.; Liao, A.; Aliaga, C.; Watts, R.; Tan, S. F.; Kaiser, J.; Shanmugavelandy, S. S.; Rogers, A.; Loughran, K.; Petersen, B.; Yuen, J.; Meng, F.; Baab, K. T.; Jarbadan, N. R.; Broeg, K.; Zhang, R.; Liao, J.; Sayers, T. J.; Kester, M.; Loughran, T. P., Jr., Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood, 2010, 116 (20), 4192-4201.
62. Wooten-Blanks, L. G.; Song, P.; Senkal, C. E.; Ogretmen, B., Mechanisms of ceramide-mediated repression of the human telomerase reverse transcriptase promoter via deacetylation of Sp3 by histone deacetylase 1. FASEB J., 2007, 21 (12), 3386-3397.
63. Beyne-Rauzy, O.; Prade-Houdellier, N.; Demur, C.; Recher, C.; Ayel, J.; Laurent, G.; Mansat-De Mas, V., Tumor necrosis factoralpha inhibits hTERT gene expression in human myeloid normal and leukemic cells. Blood, 2005, 106 (9), 3200-3205.
64. 2+ system in HL60 leukemia cells. FEBS, 1996, 379, 260-264.
65. Van Koppen, C.; Meyer, z. H. M.; Laser, K. T.; Zhang, C.; Jakobs, K. H.; Bunemann, M.; Pott, L., Activation of a high affinity Gi protein- coupled plasma membrane receptor by sphingosine-1- phosphate. J. Biol. Chem., 1996, 271 (4), 2082-2087.
66. Buehrer, B.; Bardes, E.; Bell, R., Protein kinase C-dependent regulation of human erythroleukemia (HEL) cell sphingosine kinase activity. Biochim. Biophys. Acta, 1996, 1303, 233-242.
67. Cuvillier, O.; Levade, T., Sphingosine 1-phosphate antagonizes apoptosis of human leukemia cells by inhibiting release of cytochrome c and Smac/DIABLO from mitochondria. Blood, 2001, 98, 2828-2836.
68. Kleuser, B.; Cuvillier, O.; Spiegel, S., 1Alpha, 25-dihydroxyvitamin D3 inhibits programmed cell death in HL60 cells by activation of sphingosine kinase. Cancer Res., 1998, 58, 1817-1824.
69. Nakamura, H.; Oda, T.; Hamada, K.; Hirano, T.; Shimizu, N.; Utiyama, H., Survival by Mac-1-mediated adherence and anoikis in phorbol ester-treated HL-60 cells. J. Biol. Chem., 1998, 273 (25), 15345-15351.
70. Hamada, K.; Nakamura, H.; Oda, T.; Hirano, T.; Shimizu, N.; Utiyama, H., Involvement of Mac-1-mediated adherence and sphingosine-1-phosphate in survival of phorbol ester-treated U937 cells. Biochem. Biophys. Res. Commun., 1998, 244, 745-750.
71. Alemany, R.; Meyer zu Heringdorf, D.; van Koppen, C.; Jakobs, K., Formyl peptide receptor signaling in HL-60 cells through sphingosine kinase. J. Biol. Chem., 1999, 274, 3994-3999.
72. Sobue, S.; Nemoto, S.; Murakami, M.; Ito, H.; Kimura, A.; Gao, S.; Furuhata, A.; Takagi, A.; Kojima, T.; Nakamura, M.; Ito, Y.; Suzuki, M.; Banno, Y.; Nozawa, Y.; Murate, T., Implications of sphingosine kinase 1 expression level for the cellular sphingolipid rheostat: relevance as a marker for daunorubicin sensitivity of leukemia cells. Int. J. Hematol., 2008, 87 (3), 266-275.
73. Lee, M. J.; Van Brocklyn, J. R.; Thangada, S.; Liu, C. H.; Hand, A. R.; Menzeleev, R.; Spiegel, S.; Hla, T., Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science, 1998, 279 (5356), 1552-1555.
74. Sato, K.; Murata, N.; Kon, J.; Tomura, H.; Nochi, H.; Tamoto, K.; Osada, M.; Ohta, H.; Tokumitsu, Y.; Ui, M.; Okajima, F., Downregulation of mRNA expression of Edg-3, a putative sphingosine- 1-phosphate receptor coupled to Ca2+ signaling, during differentiation of HL-60 leukemia cells. Biochem. Biophys. Res. Commun., 1998, 253, 253-256.
75. Jolly, P. S.; Bektas, M.; Watterson, K. R.; Sankala, H.; Payne, S. G.; Milstien, S.; Spiegel, S., Expression of SphK1 impairs degranulation and motility of RBL-2H3 mast cells by desensitizing S1P receptors. Blood, 2005, 105 (12), 4736-4742.
76. Kothapalli, R.; Kusmartseva, I.; Loughran, T. P., Characterization of a human sphingosine-1-phosphate receptor gene (S1P5) and its differential expression in LGL leukemia. Biochim. Biophys. Acta, 2002, 1579 (2-3), 117-123.
77. Sokol, L.; Loughran, T. P., Jr., Large granular lymphocyte leukemia. Oncologist, 2006, 11 (3), 263-273.
78. Zhang, R.; Shah, M. V.; Yang, J.; Nyland, S. B.; Liu, X.; Yun, J. K.; Albert, R.; Loughran, T. P., Jr., Network model of survival signaling in large granular lymphocyte leukemia. Proc. Natl. Acad. Sci. USA, 2008, 105 (42), 16308-16313.
79. Shah, M. V.; Zhang, R.; Irby, R.; Kothapalli, R.; Liu, X.; Arrington, T.; Frank, B.; Lee, N. H.; Loughran, T. P., Jr., Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood, 2008, 112 (3), 770-781.
80. Le Scolan, E.; Pchejetski, D.; Banno, Y.; Denis, N.; Mayeux, P.; Vainchenker, W.; Levade, T.; Moreau-Gachelin, F., Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression. Blood, 2005, 106 (5), 1808-1816.
81. Chen, Y.; Peng, C.; Li, D.; Li, S., Molecular and cellular bases of chronic myeloid leukemia. Protein & Cell, 2010, 1 (2), 124-132.
82. Baran, Y.; Salas, A.; Senkal, C. E.; Gunduz, U.; Bielawski, J.; Obeid, L. M.; Ogretmen, B., Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J. Biol. Chem., 2007, 282 (15), 10922-10934.
83. Bonhoure, E.; Pchejetski, D.; Aouali, N.; Morjani, H.; Levade, T.; Kohama, T.; Cuvillier, O., Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia, 2006, 20 (1), 95-102.
84. Marfe, G.; Di Stefano, C.; Gambacurta, A.; Ottone, T.; Martini, V.; Abruzzese, E.; Mologni, L.; Sinibaldi-Salimei, P.; de Fabritis, P.; Gambacorti-Passerini, C.; Amadori, S.; Birge, R. B., Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia (CML) cells. Exp. Hematol. 2011, (Accepted manuscript)
85. Lee, H.; Deng, J.; Kujawski, M.; Yang, C.; Liu, Y.; Herrmann, A.; Kortylewski, M.; Horne, D.; Somlo, G.; Forman, S.; Jove, R.; Yu, H., STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat. Med., 2010, 16 (12), 1421-1428.
86. Hodge, D. R.; Hurt, E. M.; Farrar, W. L., The role of IL-6 and STAT3 in inflammation and cancer. Eur. J. Cancer, 2005, 41 (16), 2502-2512.
87. Benekli, M.; Baumann, H.; Wetzler, M., Targeting signal transducer and activator of transcription signaling pathway in leukemias. J. Clin. Oncol., 2009, 27 (26), 4422-4432.
88. Stam, J.; Michiels, F.; van der Kammen, R.; Moolenaar, W.; Collard, J., Invasion of T-lymphoma cells: cooperation between Rho family GTPases and lysophospholipid receptor signaling. EMBO J., 1998, 17, 4066-4074.
89. Takuwa, Y.; Takuwa, N.; Sugimoto, N., The Edg family G proteincoupled receptors for lysophospholipids: their signaling properties and biological activities. J. Biochem., 2002, 131 (6), 767-771.
90. Ito, Y., RUNX genes in development and cancer: regulation of viral gene expression and the discovery of RUNX family genes. Adv. Cancer Res., 2008, 99, 33-76.
91. Kilbey, A.; Terry, A.; Jenkins, A.; Borland, G.; Zhang, Q.; Wakelam, M. J.; Cameron, E. R.; Neil, J. C., Runx regulation of sphingolipid metabolism and survival signaling. Cancer Res., 2010, 70 (14), 5860-5869.
92. Li, M. H.; Sanchez, T.; Pappalardo, A.; Lynch, K. R.; Hla, T.; Ferrer, F., Induction of antiproliferative connective tissue growth factor expression in Wilms' tumor cells by sphingosine-1- phosphate receptor 2. Mol. Cancer Res., 2008, 6 (10), 1649-1656.
93. Skoura, A.; Sanchez, T.; Claffey, K.; Mandala, S. M.; Proia, R. L.; Hla, T., Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina. J. Clin. Invest., 2007, 117 (9), 2506-2516.
94. Cattoretti, G.; Mandelbaum, J.; Lee, N.; Chaves, A. H.; Mahler, A. M.; Chadburn, A.; Dalla-Favera, R.; Pasqualucci, L.; MacLennan, A. J., Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation. Cancer Res., 2009, 69 (22), 8686-8692.
95. Du, W.; Takuwa, N.; Yoshioka, K.; Okamoto, Y.; Gonda, K.; Sugihara, K.; Fukamizu, A.; Asano, M.; Takuwa, Y., S1P(2), the G protein-coupled receptor for sphingosine-1-phosphate, negatively regulates tumor angiogenesis and tumor growth in vivo in mice. Cancer Res., 2010, 70 (2), 772-781.
96. Gustafsson, K.; Sander, B.; Bielawski, J.; Hannun, Y. A.; Flygare, J., Potentiation of cannabinoid-induced cytotoxicity in mantle cell lymphoma through modulation of ceramide metabolism. Mol. Cancer Res., 2009, 7 (7), 1086-1098.
97. Nishimura, H.; Akiyama, T.; Monobe, Y.; Matsubara, K.; Igarashi, Y.; Abe, M.; Sugihara, T.; Sadahira, Y., Expression of sphingosine- 1-phosphate receptor 1 in mantle cell lymphoma. Mod. Pathol., 2010, 23 (3), 439-449.
98. Bayerl, M. G.; Bruggeman, R. D.; Conroy, E. J.; Hengst, J. A.; King, T. S.; Jimenez, M.; Claxton, D. F.; Yun, J. K., Sphingosine kinase 1 protein and mRNA are overexpressed in non-Hodgkin lymphomas and are attractive targets for novel pharmacological interventions. Leuk. Lymphoma, 2008, 49 (5), 948-954.
99. Gupta, S. D.; Gable, K.; Han, G.; Borovitskaya, A.; Selby, L.; Dunn, T. M.; Harmon, J. M., Tsc10p and FVT1: topologically distinct short-chain reductases required for long-chain base synthesis in yeast and mammals. J. Lipid Res., 2009, 50 (8), 1630-1640.
100. Czuchlewski, D. R.; Csernus, B.; Bubman, D.; Hyjek, E.; Martin, P.; Chadburn, A.; Knowles, D. M.; Cesarman, E., Expression of the follicular lymphoma variant translocation 1 gene in diffuse large Bcell lymphoma correlates with subtype and clinical outcome. Am. J. Clin. Pathol., 2008, 130 (6), 957-962.
101. Li, Q.-F.; Wu, C.-T.; Guo, Q.; Wang, H.; Wang, L.-S., Sphingosine 1-phosphate induces Mcl-1 upregulation and protects multiple myeloma cells against apoptosis. Biochem. Biophys. Res. Comm., 2008, 371, 159-162.
102. Li, Q.-F.; Wu, C.-T.; Duan, H.-F.; Sun, H.-Y.; Wang, H.; Lu, Z.-Z.; Zhang, Q.-W.; Liu, H.-J.; Wang, L.-S., Activation of sphingosine kinase mediates suppressive effect of interleukin-6 on human multiple myeloma cell apoptosis. Br. J. Haematol., 2007, 138, 632-639.
103. Fujita, T.; Inoue, K.; Yamamoto, S.; Ikumoto, T.; Sasaki, S.; Toyama, R.; Chiba, K.; Hoshino, Y. T O., Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J. Antibiot. (Tokyo)., 1994, 47, 208-215.
104. Mandala, S.; Hajdu, R.; Bergstrom, J.; Quackenbush, E.; Xie, J.; Milligan, J.; Thornton, R.; Shei, G. J.; Card, D.; Keohane, C.; Rosenbach, M.; Hale, J.; Lynch, C. L.; Rupprecht, K.; Parsons, W.; Rosen, H., Alteration of lymphocyte trafficking by sphingosine-1- phosphate receptor agonists. Science, 2002, 296 (5566), 346-349.
105. Brinkmann, V.; Davis, M. D.; Heise, C. E.; Albert, R.; Cottens, S.; Hof, R.; Bruns, C.; Prieschl, E.; Baumruker, T.; Hiestand, P.; Foster, C. A.; Zollinger, M.; Lynch, K. R., The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem., 2002, 277 (24), 21453-21457.
106. Zemann, B.; Kinzel, B.; Muller, M.; Reuschel, R.; Mechtcheriakova, D.; Urtz, N.; Bornancin, F.; Baumruker, T.; Billich, A., Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood, 2006, 107 (4), 1454-1458.
107. Graler, M. H.; Goetzl, E. J., The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G protein-coupled receptors. FASEB J., 2004, 18 (3), 551-553.
108. Neviani, P.; Santhanam, R.; Oaks, J. J.; Eiring, A. M.; Notari, M.; Blaser, B. W.; Liu, S.; Trotta, R.; Muthusamy, N.; Gambacorti- Passerini, C.; Druker, B. J.; Cortes, J.; Marcucci, G.; Chen, C. S.; Verrills, N. M.; Roy, D. C.; Caligiuri, M. A.; Bloomfield, C. D.; Byrd, J. C.; Perrotti, D., FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome- positive acute lymphocytic leukemia. J. Clin. Invest., 2007, 117 (9), 2408-2421.
109. Fujino, M.; Li, X. K.; Kitazawa, Y.; Guo, L.; Kawasaki, M.; Funeshima, N.; Amano, T.; Suzuki, S., Distinct pathways of apoptosis triggered by FTY720, etoposide, and anti-Fas antibody in human T-lymphoma cell line (Jurkat cells). J. Pharmacol. Exp. Ther., 2002, 300 (3), 939-945.
110. Nagahara, Y.; Matsuoka, Y.; Saito, K.; Ikekita, M.; Higuchi, S.; Shinomiya, T., Coordinate involvement of cell cycle arrest and apoptosis strengthen the effect of FTY720. Jpn. J. Cancer Res., 2001, 92 (6), 680-687.
111. Yasui, H.; Hideshima, T.; Raje, N.; Roccaro, A. M.; Shiraishi, N.; Kumar, S.; Hamasaki, M.; Ishitsuka, K.; Tai, Y. T.; Podar, K.; Catley, L.; Mitsiades, C. S.; Richardson, P. G.; Albert, R.; Brinkmann, V.; Chauhan, D.; Anderson, K. C., FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res., 2005, 65 (16), 7478-7484.
112. Roberts, K. G.; Smith, A. M.; McDougall, F.; Carpenter, H.; Horan, M.; Neviani, P.; Powell, J. A.; Thomas, D.; Guthridge, M. A.; Perrotti, D.; Sim, A. T.; Ashman, L. K.; Verrills, N. M., Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res., 2010, 70 (13), 5438-5447.
113. Cristobal, I.; Garcia-Orti, L.; Cirauqui, C.; Alonso, M. M.; Calasanz, M. J.; Odero, M. D., PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia, 2011.
114. Sabbadini, R. A., Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration. Br. J. Pharmacol., 2011, 162 (6), 1225-1238.
115. Ohta, H.; Sweeney, E.; Masamune, A.; Yatomi, Y.; Hakomori, S.; Igarashi, Y., Induction of apoptosis by sphingosine in human leukemic HL-60 cells: a possible endogenous modulator of apoptotic DNA fragmentation occurring during phorbol ester-induced differentiation. Cancer Res., 1995, 55 (3), 691-697.
116. Coward, J.; Ambrosini, G.; Musi, E.; Truman, J. P.; Haimovitz- Friedman, A.; Allegood, J. C.; Wang, E.; Merrill, A. H., Jr.; Schwartz, G. K., Safingol (L-threo-sphinganine) induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway. Autophagy, 2009, 5 (2), 184-193.
117. Dickson, M. A.; Carvajal, R. D.; Merrill, A. H.; Gonen, M.; Cane, L. M.; Schwartz, G. K., A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clin. Cancer Res., 2011.
118. Schwartz, G. K.; Ward, D.; Saltz, L.; Casper, E. S.; Spiess, T.; Mullen, E.; Woodworth, J.; Venuti, R.; Zervos, P.; Storniolo, A. M.; Kelsen, D. P., A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin. Clin. Cancer Res., 1997, 3 (4), 537-543.
119. Paugh, S. W.; Paugh, B. S.; Rahmani, M.; Kapitonov, D.; Almenara, J. A.; Kordula, T.; Milstien, S.; Adams, J. K.; Zipkin, R. E.; Grant, S.; Spiegel, S., A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood, 2008, 112 (4), 1382-1391.
120. Beljanski, V.; Knaak, C.; Smith, C. D., A novel sphingosine kinase inhibitor induces autophagy in tumor cells. J. Pharmacol. Exp. Ther., 2010, 333 (2), 454-464.
121. Azuma, H.; Takahara, S.; Ichimaru, N.; Wang, J. D.; Itoh, Y.; Otsuki, Y.; Morimoto, J.; Fukui, R.; Hoshiga, M.; Ishihara, T.; Nonomura, N.; Suzuki, S.; Okuyama, A.; Katsuoka, Y., Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res., 2002, 62 (5), 1410-1419.
122. Azuma, H.; Takahara, S.; Horie, S.; Muto, S.; Otsuki, Y.; Katsuoka, Y., Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J. Urol. 2003, 169 (6), 2372-237.
123. Sweeney, E. A.; Sakakura, C.; Shirahama, T.; Masamune, A.; Ohta, H.; Hakomori, S.; Igarashi, Y., Sphingosine and its methylated derivative N,N-dimethylsphingosine (DMS) induce apoptosis in a variety of human cancer cell lines. Int. J. Cancer 1996, 66 (3), 358-366.
124. Park, S. R.; Cho, H. J.; Moon, K. J.; Chun, K. H.; Kong, S. Y.; Yoon, S. S.; Lee, J. S.; Park, S., Cytotoxic effects of novel phytosphingosine derivatives, including N,N-dimethylphytosphingosine and N-monomethylphytosphingosine, in human leukemia cell line HL60. Leuk. Lymphoma, 2010, 51 (1), 132-145.
125. Fyrst, H.; Oskouian, B.; Bandhuvula, P.; Gong, Y.; Byun, H. S.; Bittman, R.; Lee, A. R.; Saba, J. D., Natural sphingadienes inhibit Akt-dependent signaling and prevent intestinal tumorigenesis. Cancer Res., 2009, 69 (24), 9457-9464.
126. Visentin, B.; Vekich, J.; Sibbald, B.; Cavalli, A.; Moreno, K.; Matteo, R.; Garland, W.; Lu, Y.; Yu, S.; Hall, H.; Kundra, V.; Mills, G.; Sabbadini, R., Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell, 2006, 9, 225-238.
127. Elojeimy, S.; Liu, X.; McKillop, J. C.; El-Zawahry, A. M.; Holman, D. H.; Cheng, J. Y.; Meacham, W. D.; Mahdy, A. E.; Saad, A. F.; Turner, L. S.; Cheng, J.T A. D.; Dong, J. Y.; Bielawska, A.; Hannun, Y. A.; Norris, J. S., Role of acid ceramidase in resistance to FasL: therapeutic approaches based on acid ceramidase inhibitors and FasL gene therapy. Mol. Ther., 2007, 15 (7), 1259-1263.
128. Saad, A. F.; Meacham, W. D.; Bai, A.; Anelli, V.; Elojeimy, S.; Mahdy, A. E.; Turner, L. S.; Cheng, J.; Bielawska, A.; Bielawski, J.; Keane, T. E.; Obeid, L. M.; Hannun, Y. A.; Norris, J. S.; Liu, X., The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol. Ther., 2007, 6 (9), 1455-1460.
129. Liu, X.; Elojeimy, S.; Turner, L. S.; Mahdy, A. E.; Zeidan, Y. H.; Bielawska, A.; Bielawski, J.; Dong, J. Y.; El-Zawahry, A. M.; Guo, G. W.; Hannun, Y. A.; Holman, D. H.; Rubinchik, S.; Szulc, Z.; Keane, T. E.; Tavassoli, M.; Norris, J. S., Acid ceramidase inhibition: a novel target for cancer therapy. Front. Biosci., 2008, 13, 2293-2298.
130. Mahdy, A. E.; Cheng, J. C.; Li, J.; Elojeimy, S.; Meacham, W. D.; Turner, L. S.; Bai, A.; Gault, C. R.; McPherson, A. S.; Garcia, N.; Beckham, T. H.; Saad, A.; Bielawska, A.; Bielawski, J.; Hannun, Y. A.; Keane, T. E.; Taha, M. I.; Hammouda, H. M.; Norris, J. S.; Liu, X., Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. Mol. Ther., 2009, 17 (3), 430-438.
131. Kim, Y. J.; Kim, E. A.; Sohn, U. D.; Yim, C. B.; Im, C., Cytotoxic Activity and Structure Activity Relationship of Ceramide Analogues in Caki-2 and HL-60 Cells. Korean J. Physiol. Pharmacol., 2010, 14 (6), 441-447.
132. Gouaze-Andersson, V.; Flowers, M.; Karimi, R.; Fabrias, G.; Delgado, A.; Casas, J.; Cabot, M. C., Inhibition of acid ceramidase by a 2-substituted aminoethanol amide synergistically sensitizes prostate cancer cells to N-(4-hydroxyphenyl) retinamide. Prostate 2010.
133. Dobrowsky, R.; Werner, M.; Castellino, A.; Chao, M.; Hannun, Y., Activation of the sphingomyelin cycle through the low-affinity neurotrophin receptor. Science, 1994, 265, 1596-1599.
134. Chao, R.; Kahn, W.; Hannun, Y., Retinoblastoma protein dephosphorylation induced by D-erythro-sphingosine. J. Biol. Chem., 1992, 267 (33), 23459-23462.
135. Jiang, Q.; Wong, J.; Fyrst, H.; Saba, J. D.; Ames, B. N., gamma- Tocopherol or combinations of vitamin E forms induce cell death in human prostate cancer cells by interrupting sphingolipid synthesis. Proc. Natl. Acad. Sci. USA, 2004, 101 (51), 17825-17830.
136. Kraveka, J.; Li, L.; Szulc, Z.; Bielawski, J.; Ogretmen, B.; Hannun, Y.; Obeid, L.; Bielawska, A., Involvement of dihydroceramide desaturase in cell cycle progression in human neuroblastoma cells. J. Biol. Chem., 2007, 282, 16718-16728.
137. Kumar, A.; Byun, H. S.; Bittman, R.; Saba, J. D., The sphingolipid degradation product trans-2-hexadecenal induces cytoskeletal reorganization and apoptosis in a JNK-dependent manner. Cell. Signal., 2011.
138. Kumar, A.; Oskouian, B.; Fyrst, H.; Zhang, M.; Paris, F.; Saba, J. D., S1P lyase regulates DNA damage responses through a novel sphingolipid feedback mechanism. Cell Death Dis., 2011, 2 (1), e119.
139. O'Leary, M.; Krailo, M.; Anderson, J. R.; Reaman, G. H., Progress in childhood cancer: 50 years of research collaboration, a report from the Children's Oncology Group. Semin. Oncol.,2008, 35 (5), 484-493.
140. Paris, F.; Perez, G.; Fuks, Z.; Haimovitz-Friedman, A.; Nguyen, H.; Bose, M.; Ilagan, A.; Hunt, P.; Morgan, W.; Tilly, J.; Kolesnick, R., Sphingosine-1-phosphate preserves fertility in irradiated female mice without propagating genomic damage in offspring. Nat. Med., 2002, 8, 901-902.
141. Bonnaud, S.; Niaudet, C.; Legoux, F.; Corre, I.; Delpon, G.; Saulquin, X.; Fuks, Z.; Gaugler, M. H.; Kolesnick, R.; Paris, F., Sphingosine-1-phosphate activates the AKT pathway to protect small intestines from radiation-induced endothelial apoptosis. Cancer Res., 2010, 70 (23), 9905-9915.
142. Maj, J.; Paris, F.; Haimovitz-Friedman, A.; Venkatraman, E.; Kolesnick, R.; Fuks, Z., Microvascular function regulates intestinal crypt response to radiation. Cancer Res., 2003, 63 (15), 4338-4341.
143. Rotolo, J. A.; Mesicek, J.; Maj, J.; Truman, J. P.; Haimovitz- Friedman, A.; Kolesnick, R.; Fuks, Z., Regulation of ceramide synthase- mediated crypt epithelium apoptosis by DNA damage repair enzymes. Cancer Res., 2010, 70 (3), 957-967.
144. Kim, Y. M.; Sachs, T.; Asavaroengchai, W.; Bronson, R.; Sykes, M., Graft-versus-host disease can be separated from graft-versuslymphoma effects by control of lymphocyte trafficking with FTY720. J. Clin. Invest., 2003, 111 (5), 659-669.
145. Bandhuvula, P.; Honbo, N.; Wang, G. Y.; Jin, Z. Q.; Fyrst, H.; Zhang, M.; Borowsky, A. D.; Dillard, L.; Karliner, J. S.; Saba, J. D., S1P lyase (SPL): a novel therapeutic target for ischemia/ reperfusion injury of the heart. Am. J. Physiol. Heart Circ. Physiol., 2011.
146. Zhao, Y.; Gorshkova, I.; Berdyshev, E.; He, D.; Fu, P.; Ma, W.; Su, Y.; Usatyuk, P.; Pendyala, S.; Oskouian, B.; Saba, J.; Garcia, J.; Natarajan, V., Protection of LPS-induced murine acute lung injury by sphingosine-1-phosphate lyase suppression. Am. J. Respir. Cell Mol. Biol., 2011.(in prsee)